{"filings":[{"id":2078956,"accession_number":"0001193125-26-335101","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-08-05T20:10:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q2 net loss $32.5M; positive Phase 1 data for ELVN-001 in CML; cash $895M into 2030","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.5M for Q2 2026 vs $25.3M in Q2 2025; R&D expenses $29.0M.","Cash, cash equivalents and marketable securities of $895.2M as of June 30, 2026, expected to fund operations into 2030.","ELVN-001 Phase 1 data: 61% overall MMR, 48% MMR by 24 weeks in 80mg QD cohort; favorable safety profile.","FDA alignment on Phase 3 ENABLE-2 trial design; 80mg QD selected as recommended dose; Fast Track Designation granted.","Expect to initiate ENABLE-2 Phase 3 trial in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1029277,"accession_number":"0001193125-26-269635","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-06-12T20:55:55+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 8,933,334 shares at $37.50/share and 1,733,333 pre-funded warrants at $37.499 each.","Gross proceeds ~$400M; net proceeds ~$376M (or ~$432.4M if underwriters' option fully exercised).","Underwriters granted 30-day option to purchase up to 1,600,000 additional shares.","Offering expected to close June 15, 2026; joint book-runners: Jefferies, Goldman Sachs, Morgan Stanley, Barclays.","Net proceeds for general corporate purposes and pipeline advancement (no specific allocation disclosed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982476,"accession_number":"0001193125-26-266731","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-06-11T12:09:27+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Enliven reports 61% overall MMR at 80 mg QD in Phase 1b; FDA aligns on Phase 3 design for ELVN-001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["161 patients enrolled; median treatment duration 35 weeks; 76% remain on study as of March 10, 2026 cutoff.","61% overall MMR and 48% achieved MMR by 24 weeks in the 80 mg QD Phase 1b cohort (n=28 evaluable).","70% of patients had 3+ prior TKIs; 62% had prior asciminib; response rates comparable regardless of prior asciminib exposure.","Only 6% discontinued due to adverse events; Grade ≥3 TEAEs at 80 mg QD were 24% with thrombocytopenia the most common at 6%.","FDA endorsed 80 mg QD as Phase 3 dose and 2L+ patient population; ENABLE-2 pivotal trial expected to initiate H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":954216,"accession_number":"0001193125-26-264085","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-06-09T21:32:31+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Enliven Therapeutics doubles authorized common shares to 200M, annual meeting votes pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment increasing authorized common shares from 100M to 200M; effective June 9, 2026.","Elected Class III directors Richard Fair and Lori Kunkel with 99.7% and 64.7% of votes cast, respectively.","Ratified Deloitte & Touche as independent auditor for FY2026 with overwhelming support (56.1M for).","Advisory say-on-pay approved (47.6M for, 89.5% of votes cast); advisory vote on frequency set to every one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94571,"accession_number":"0001193125-26-211921","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven reports Q1 net loss of $23.6M; cash $452.4M; ELVN-001 Phase 1 data mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.6M in Q1 2026 vs. $28.5M in Q1 2025; R&D spend $20.7M.","Cash, cash equivalents and marketable securities of $452.4M as of March 31, 2026; runway into first half of 2029.","Phase 1 data update for ELVN-001 expected mid-2026; Phase 3 ENABLE-2 initiation expected H2 2026.","ELVN-001 is a potentially best-in-class ATP-competitive BCR::ABL inhibitor for CML."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107053,"accession_number":"0001193125-26-088195","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.","Cash, equivalents and marketable securities $462.6M, providing runway into first half of 2029.","Initial Phase 1b data: MMR achieved in 47% (80 mg QD) and 69% (60/120 mg QD) of evaluable patients.","Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected to initiate in second half of 2026.","Rick Fair appointed CEO in December 2025; Scott Garland added to board in January 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107052,"accession_number":"0001193125-26-005535","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.","Garland receives $40k annual cash (director) + $10k (committee chair) and initial stock option grant with ~$650k fair value vesting over 3 years.","Andrew Phillips resigned from board and committees effective Jan 7, 2026; resignation not due to any disagreement with company.","Garland brings biopharma commercial expertise as company advances ELVN-001 toward Phase 3 pivotal trial in CML in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123393,"accession_number":"0001193125-25-315196","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Fair appointed President, CEO and board member, effective December 11, 2025.","Co-founder Sam Kintz transitions to Head of Pipeline, remains at Enliven.","Fair receives $660,000 base salary, 55% target bonus, and option award for 875,000 shares.","Kintz receives $500,000 base salary, 55% bonus, and acceleration of 140,457 stock options.","Company plans to initiate Phase 3 trial for ELVN-001 in CML in 2026, citing need for commercialization expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123391,"accession_number":"0001193125-25-278466","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K/A","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q3 2025 net loss $20.1M; completed Phase 1b enrollment for ELVN-001 in CML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment of randomized Phase 1b cohorts of ENABLE trial of ELVN-001 in CML; on track for Phase 3 pivotal trial in 2026.","Cash, equivalents and marketable securities of $477.6M at Sep 30, 2025, expected to fund operations into first half 2029.","Net loss of $20.1M for Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M, G&A $6.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123392,"accession_number":"0001193125-25-277580","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.","Cash, cash equivalents and marketable securities $477.6M; runway into first half 2029.","Completed randomized Phase 1b portion of ENABLE trial evaluating ELVN-001 in CML patients.","On track to initiate Phase 3 pivotal trial for ELVN-001 in 2026.","Data from ELVN-001 in CML patients with atypical fusion transcripts to be presented at ASH 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140055,"accession_number":"0001193125-25-179837","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.","Cash, cash equivalents and marketable securities $490.5M as of June 30, 2025; cash runway into first half of 2029.","Net loss of $25.3M for Q2 2025 vs $20.0M in Q2 2024; R&D expenses $21.5M, G&A $7.1M.","Company plans to initiate Phase 3 pivotal trial of ELVN-001 in 2026.","Recent public offering generated $230M gross proceeds, strengthening balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157703,"accession_number":"0001193125-25-146874","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Enliven Therapeutics stockholders elect three Class II directors, ratify Deloitte as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class II directors: Rahul D. Ballal (36,870,420 for), Jake Bauer (37,250,826 for), Andrew Phillips (31,957,928 for).","Ratified Deloitte & Touche LLP as independent auditor for FY2025 (45,392,647 for, 2,435 against, 35,215 abstain).","Broker non-votes of 8,099,804 existed for director elections; ratification had no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157702,"accession_number":"0001193125-25-141085","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.","Underwriters granted 30-day option to purchase additional 1.53M shares; expected close June 16, 2025.","Net proceeds including option exercise expected ~$216.1M, for working capital and general corporate purposes.","Joint book-runners: Jefferies, Goldman Sachs, TD Cowen, Mizuho; LifeSci Capital as lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157701,"accession_number":"0001193125-25-140285","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Enliven reports 47% cumulative MMR by 24 weeks for ELVN-001 in Phase 1 CML trial; well-tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["47% of evaluable patients (25/53) achieved MMR by 24 weeks; 32% (13/41) achieved MMR, comparing favorably to asciminib's 24% in Phase 1.","90 patients enrolled; 80% remain on study with median treatment duration ~29 weeks; heavily pretreated (67% received ≥3 prior TKIs).","Safety: only 3.4% dose reductions, 4.6% discontinuations due to AEs; no treatment-related arterial occlusive events; no MTD reached.","PK supports once-daily dosing with food flexibility and low drug-drug interaction potential.","Company expects to initiate first head-to-head Phase 3 pivotal trial in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157700,"accession_number":"0000950170-25-071387","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.","Cash, equivalents and marketable securities $289.6M; runway into late 2027.","ELVN-001 Phase 1 ENABLE: 44% (16/36) cumulative MMR by 24 weeks, well-tolerated, 74 patients.","Strategic alternatives for ELVN-002 program; not pursued beyond 2025 to extend cash runway.","Updated ELVN-001 data to be presented at EHA Congress in June; webcast June 13."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176071,"accession_number":"0000950170-25-038737","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).","Cash, cash equivalents and marketable securities $313.4M as of Dec 31, 2024; cash runway into mid-2027.","R&D expenses $20.7M in Q4 2024 ($17.9M Q4 2023); full year $80.8M ($64.6M FY2023).","ELVN-001 Phase 1 data expected mid-2025; ELVN-002 Phase 1 data expected H2 2025; FDA orphan drug designation.","First patient dosed in Japanese Phase 1 trial for ELVN-001; ELVN-002 combination trials enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192985,"accession_number":"0000950170-24-126323","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Q3 net loss $23.2M; ELVN-001 Phase 1 MMR rate 44% by 24 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $291.8M as of Sept 30, 2024; runway into late 2026.","Net loss $23.2M (Q3 2024) vs $20.8M (Q3 2023); R&D expenses $21.3M.","ELVN-001 Phase 1: cumulative MMR 44% (8/18) by 24 weeks; no dose reductions at ≥40 mg due to TRAEs.","Plan to report additional ELVN-001 data in 2025 with ~60-100 patients across lines of therapy.","ELVN-002 trials in HER2+ MBC and CRC ongoing; data anticipated in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209358,"accession_number":"0000950170-24-096204","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q2 net loss $20.0M; cash $312.4M; pipeline advances with ELVN-001/002 dosing starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.","Q2 2024 net loss $20.0M ($16.7M Q2 2023); R&D expense $18.8M ($15.2M), G&A $5.8M ($5.0M).","ELVN-001 Phase 1b arm dosing initiated in CML patients; abstract accepted for September ESH-iCMLf conference.","ELVN-002 Phase 1a combo trial with trastuzumab +/- chemo and exploratory arm with Kadcyla dosed first patients.","Phase 1 data for ELVN-001 and initial ELVN-002 combo data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227353,"accession_number":"0001193125-24-163507","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Enliven shareholders approve 2.9M share increase in equity plan and officer exculpation amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 2,900,000.","Certificate of Incorporation amended to limit officer liability for monetary damages under Delaware law.","Class I directors Mika Derynck (36.4M for) and Rishi Gupta (37.4M for) elected to 2027 annual meeting.","Deloitte & Touche LLP ratified as independent auditor for FY 2024 with 42.9M votes for.","All proposals passed; broker non-votes 4.6M on director elections and other items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227349,"accession_number":"0001193125-24-149141","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K/A","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Enliven Therapeutics appoints director Lori Kunkel to Nominating Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lori Kunkel appointed to Nominating and Corporate Governance Committee effective May 29, 2024.","Her board appointment was reported April 9, 2024; committee role now determined.","Appointment follows recommendation of the Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227352,"accession_number":"0000950170-24-059544","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.","ELVN-001 Phase 1 proof-of-concept: 44% (7/16) cumulative MMR rate by week 12 in response-evaluable CML patients.","Entered $90M PIPE financing from new/existing investors; expected cash runway into late 2026.","Appointed Dr. Lori Kunkel to Board of Directors.","Activated first site for ELVN-002 combo trial with trastuzumab in HER2+ cancers; first dosing expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227351,"accession_number":"0001193125-24-092522","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.","No ≥ Grade 3 non-hematologic treatment-related adverse events; well tolerated with no dose reductions.","ELVN-001 at ≥40mg QD shows superior target coverage vs 2nd-gen TKIs; PK supports once-daily dosing with no food effect.","89% of all enrolled patients remain on study; maximum tolerated dose not yet identified.","Company hosting virtual event with key opinion leaders at 8:00 AM ET today to discuss data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227350,"accession_number":"0001193125-24-090821","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enliven Therapeutics appoints Dr. Lori Kunkel to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kunkel appointed as Class III director, term expiring at 2026 annual meeting.","Annual cash retainer of $35,000; stock option grant with fair value ~$500,000 vesting monthly over 3 years.","No arrangements or transactions requiring disclosure under Item 404(a) of Reg S-K.","Dr. Kunkel brings 25+ years oncology drug development experience; previously scientific advisor to Enliven."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246222,"accession_number":"0001193125-24-070839","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Enliven Therapeutics raises $90M in PIPE, extends cash runway into late 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$90M from sale of 5.36M shares at $14.00 and pre-funded warrants at $13.999.","PIPE priced at ~11% premium to March 18 close; expected to close March 21, 2024.","Proceeds plus existing cash expected to fund operations into late 2026 and through key clinical milestones.","ELVN-001 Phase 1a proof-of-concept data to be presented at KOL event on April 11, 2024.","ELVN-002 combination trial first patient dosing expected in Q2 2024; Phase 1 data in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246221,"accession_number":"0000950170-24-031482","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven reports 2023 net loss $71.6M; cash $253M; ELVN-001 data due Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $71.6M for full year 2023, up from $37.7M in 2022; R&D spend $64.6M.","Cash, cash equivalents and marketable securities $253.1M; expected runway into early 2026.","Phase 1a ELVN-001 proof-of-concept data expected Q2 2024 (n>20 patients at efficacious dose).","ELVN-002 IND cleared for combination with trastuzumab in HER2+ cancers; first patient dosing by mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263661,"accession_number":"0000950170-23-062042","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q3 net loss $20.8M; cash $263.5M; ELVN-001/002 data on track for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $263.5M as of Sept 30, 2023; expected runway into early 2026.","Net loss $20.8M vs $10.6M in Q3 2022; R&D expense $19.6M (up from $7.8M); G&A $4.6M (up from $3.1M).","ELVN-001 (CML) and ELVN-002 (HER2-altered solid tumors) Phase 1 trials enrolling; initial proof-of-concept data expected in 2024.","Third IND-enabling study completed; additional pipeline details and guidance planned for H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280883,"accession_number":"0000950170-23-041322","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q2 2023 net loss $16.7M; cash $277.9M; Phase 1 data expected 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.7M for Q2 2023, compared to $8.9M in Q2 2022.","Cash, cash equivalents and marketable securities total $277.9M as of June 30, 2023.","R&D expenses $15.2M vs $7.9M; G&A expenses $5.0M vs $1.1M (year-over-year).","Phase 1 trials for ELVN-001 (CML) and ELVN-002 (HER2+) advancing with initial safety/efficacy data expected in 2024.","Third program product candidate selected; more details to be disclosed in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299538,"accession_number":"0001193125-23-174006","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Enliven Therapeutics signs $200M ATM equity distribution agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with Jefferies allows issuance of up to $200M in common stock at 3.0% commission rate.","Prior Cantor Fitzgerald ATM terminated; had raised $1.4M of its $75M capacity before termination.","Proceeds to fund R&D for ELVN-001, ELVN-002, other preclinical programs, and general corporate purposes.","Registration Statement (S-3) filed but not yet effective; no sales may occur until declared effective by SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299537,"accession_number":"0001193125-23-173796","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Enliven Therapeutics recasts FY2022 financials after reverse split; reports net loss of $37.7M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting elected directors Heyman and Kintz; ratified Deloitte & Touche as auditor for FY2023.","Recasted FY2022 net loss of $37.7M ($12.05 per share) vs $24.7M in FY2021.","R&D expense rose 51% to $31.0M; G&A expense increased to $7.8M.","Cash and equivalents totaled $75.5M at Dec 31, 2022, down from $110.0M a year earlier.","Company expects current cash to fund operations for at least 12 months from March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299536,"accession_number":"0001193125-23-142019","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q1 net loss $14.7M; cash $292.1M; dosed first patient in ELVN-002 Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.7M for Q1 2023 vs $8.7M in Q1 2022; R&D expenses $11.9M, G&A $4.5M.","Cash and equivalents $292.1M as of March 31, 2023, expected to fund operations into early 2026.","Dosed first patient in Phase 1 trial of ELVN-002 for HER2-altered NSCLC and other solid tumors.","Enrollment progressing in Phase 1 trial of ELVN-001 for CML; initial safety/efficacy data expected in 2024.","Completed merger with Imara Inc. in February 2023; shares now trade as ELVN on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319673,"accession_number":"0001193125-23-075736","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K/A","filed_at":"2023-03-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Enliven Therapeutics files audited FY2022 financials with net loss of $37.7M; pro forma cash from $164.5M financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $37.7M for year ended Dec 31, 2022 vs $24.7M in 2021; R&D spend rose 51% to $31.0M.","Cash and equivalents of $75.5M at Dec 31, 2022; $164.5M PIPE closed concurrently with merger on Feb 23, 2023.","Pro forma financials reflect reverse recapitalization with Imara Inc.; Enliven is accounting acquirer.","Accumulated deficit of $82.9M; company expects current cash to fund ops for at least 12 months.","Audited balance sheet shows total assets of $83.3M and total liabilities of $10.4M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319674,"accession_number":"0001193125-23-056303","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["1.01","2.01","5.02","3.03","4.01","5.01","5.03","5.05","8.01","9.01"],"status":"ready","headline":"Imara completes reverse merger with Enliven; combined company to trade as ELVN","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Feb 23, 2023; exchange ratio ~0.2951; ~41.1M shares outstanding post-merger.","Former Enliven shareholders own ~84% of combined company; Imara shareholders ~16%.","Imara shareholders receive one CVR per share for potential payments from tovinontrine sale to Cardurion.","New leadership: Sam Kintz (CEO), Benjamin Hohl (CFO); prior Imara CEO and CFO resigned with severance.","Auditor changed from EY to Deloitte; 1-for-4 reverse stock split; ticker changes to ELVN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319676,"accession_number":"0001193125-23-044902","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["3.03","5.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Imara stockholders approve merger with Enliven Therapeutics, authorize reverse stock split and share increase","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders approved issuance of shares for merger with Enliven Therapeutics (21.4M for, 29K against).","Authorized increase in common shares from 200M to 400M; approved reverse stock split at ratio of 1:3 to 1:7.","Adopted Amended and Restated 2020 Equity Incentive Plan and increased ESPP shares to 1,628,535.","Special meeting held Feb 22, 2023; all six proposals passed with requisite votes.","Press release issued announcing voting results and reverse stock split details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319675,"accession_number":"0001193125-23-036052","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Imara supplements merger proxy with lawsuit update and executive compensation details","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Lawsuit filed Nov 23, 2022 voluntarily dismissed Jan 19, 2023; Imara says meritless.","Pipeline chart updated: ELVN-002 advanced to Phase 1 clinical trial.","SVB Securities received $2.2M fees from Imara in past 2 years; disclosed as supplemental.","Post-merger: Kintz base salary to $550K, Collins to $465K, Hohl to $410K; bonus targets increased.","Enliven executives to receive change-in-control severance with 12-18 months salary and equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337881,"accession_number":"0001193125-22-298474","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Imara Inc. announces expiration of HSR Act waiting period for merger with Enliven Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["HSR Act waiting period for merger with Enliven Therapeutics expired on Nov 28, 2022, without extension or request for additional information.","This expiration satisfies one of the conditions to closing the merger previously announced on Oct 13, 2022.","Upon closing, Merger Sub will merge with Enliven, making Enliven a wholly-owned subsidiary of Imara."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337877,"accession_number":"0001193125-22-285963","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K/A","filed_at":"2022-11-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Imara sells PDE9 program (tovinontrine) to Cardurion for $35M upfront plus milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash of $34.75M at closing plus $250K previously received; net proceeds ~$32.75M after ~$2M costs.","Potential milestone payments: $10M for clinical proof-of-concept, $50M for regulatory/commercial events.","Pro forma cash at Sep 30, 2022 rises to $82.2M; net loss for 9M 2022 falls from $30.7M to $13.0M.","R&D expenses eliminated from $18.8M to $1.1M for 9M 2022 as sold asset costs are removed.","Imara retains no further involvement in development or commercialization of the sold assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337880,"accession_number":"0001193125-22-282630","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.01","5.07","9.01"],"status":"ready","headline":"Imara completes sale of tovinontrine and PDE9 assets to Cardurion for $34.75M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed asset sale on Nov 10, 2022; received $34.75M upfront cash payment from Cardurion.","Stockholders approved sale at special meeting on Nov 9: 18,366,825 for, 11,907 against, 47,876 abstain.","Eligible for up to $10M proof-of-concept milestone and $50M regulatory/commercial milestones.","Pro forma financial information to be filed within four business days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337879,"accession_number":"0001193125-22-262375","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Imara and Enliven hold investor call on definitive merger; Enliven to become wholly owned subsidiary","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Merger agreement provides for Enliven to survive as wholly owned subsidiary of Imara via a reverse merger.","Joint investor conference call held on October 13, 2022 to discuss the transaction and its rationale.","No deal value, premium, or expected close date disclosed in this filing or the appended transcript excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337878,"accession_number":"0001193125-22-262210","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-10-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Imara to merge with Enliven; Enliven stockholders to own ~84% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enliven valued at $324.6M plus $164.5M financing; Imara valued at net cash plus $10M.","Pre-merger Imara stockholders to own ~16% of combined co; CVRs tied to asset sale/IMR-261.","Concurrent $164.5M Enliven PIPE; closing conditioned on Imara asset sale, HSR, stockholder votes.","Board: 8 Enliven designees, 1 Imara (CEO Rahul Ballal); reverse stock split planned.","Termination fees: Imara pays $3M, Enliven pays $9.75M under specified conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355236,"accession_number":"0001193125-22-239422","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Imara sells PDE9 program (tovinontrine) to Cardurion for $34.75M upfront plus milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Imara to receive $34.75M upfront at closing for tovinontrine and all PDE9 assets; plus $250k previously paid.","Potential milestone payments: $10M for proof-of-concept/clinical milestones, $50M for regulatory/commercial milestones.","Transaction requires stockholder approval; Board unanimously approved; termination fee of $1.5M.","Retention agreements amended for CEO Rahul Ballal and CFO/COO Michael Gray, with 50% payable on definitive agreement and 50% on closing.","Company will continue evaluating strategic alternatives post-sale, including possible liquidation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355235,"accession_number":"0001564590-22-027108","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Imara terminates Boston office lease early; pays $315k fee to reduce costs while exploring strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated 9,236 sq ft office lease set to expire March 2027; termination contingent on landlord finding a new tenant.","Paid one-time termination fee of $315,000; Landlord may draw $175k existing letter of credit plus $140k cash.","Early termination intended to reduce operating expenses amid ongoing comprehensive strategic review to maximize stockholder value.","If no new lease executed within 30 days, or landlord terminates, agreement is void and partial termination fee returned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373364,"accession_number":"0001564590-22-022471","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Imara Inc. reports annual meeting results; elects directors, ratifies EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Rahul D. Ballal and Barbara J. Dalton as Class II directors for three-year terms expiring 2025.","Ballal received 11,789,401 votes for and 1,791,276 withheld; Dalton had 11,786,912 for and 1,793,765 withheld.","Ratification of Ernst & Young as independent auditor for FY 2022 passed with 18,806,373 votes for, 60,227 against, 46,749 abstentions.","Meeting held on June 2, 2022; broker non-votes on director elections totaled 5,332,673."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373363,"accession_number":"0001564590-22-014494","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["2.0","5.02","8.01"],"status":"ready","headline":"Imara cuts 83% of workforce, ends all pipeline programs, reviews strategic options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~83% leaves only 6 full-time employees; substantially complete by Q2 2022.","Discontinues tovinontrine (IMR-687) in sickle cell, beta-thalassemia, and heart failure with preserved ejection fraction.","Also discontinues development of IMR-261; company starts comprehensive strategic review to maximize shareholder value.","One-time restructuring charge of $2.0-2.2 million expected in Q2 2022 for severance and benefits.","Chief Medical Officer Kenneth Attie, M.D. departs effective April 20, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392094,"accession_number":"0001564590-22-010212","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imara reports FY2021 net loss $51.4M; interim Phase 2b data expected April 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.4M ($2.37 per share) vs $49.2M ($3.53 per share) in FY2020; cash $90.3M at Dec 31, 2021.","Phase 2b SCD and beta-thalassemia trials fully enrolled; interim data from both trials expected first week of April 2022.","FDA required change of Ardent SCD trial primary endpoint to annualized VOC rate; conduct unchanged.","Added HFpEF indication for tovinontrine; Phase 2 trial dosing expected Q2 2022; pipeline expanded with IMR-261.","FY2022 guidance: R&D $60-65M, G&A $13-15M; cash runway through Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410421,"accession_number":"0001564590-21-055442","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imara reports Q3 net loss $13.6M; tovinontrine Phase 2b interim data expected Q4 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.6M ($0.55/share) vs $12.4M ($0.72/share) in Q3 2020; cash & investments $102.8M.","R&D expenses $10.4M; FY2021 R&D guidance $40-45M, G&A $12-13M; cash runway into Q1 2023.","Phase 2b Ardent (SCD) and Forte (beta-thalassemia) trials fully enrolled; interim data Q4 2021, primary analysis Q1 2022.","New pipeline asset IMR-261 (Nrf2 activator) acquired; preclinical data to be presented at ASH 2021.","Hired cardiologist Dr. Toni Bransford to lead HFpEF Phase 2 trial of tovinontrine; trial expected to start 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410420,"accession_number":"0001564590-21-051756","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2021-10-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Sara Nayeem to resign from IMARA board effective Nov 15, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sara Nayeem announced resignation from the board of directors on October 21, 2021.","Resignation effective November 15, 2021, due to a change in her employment.","No replacement announced; board size will decrease by one member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429218,"accession_number":"0001564590-21-041896","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2021-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imara Q2 net loss $13.2M; IMR-687 SCD trial fully enrolled; interim data Q4 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.2M ($0.74/share) vs $10.2M ($0.59) in Q2 2020.","Cash $66.8M at June 30; $50M July offering extends runway through 2022.","SCD Phase 2b (Ardent) enrollment complete; primary analysis Q1 2022, interim Q4 2021.","Beta-thalassemia Phase 2b (Forte) TDT cohort fully enrolled; interim data Q4 2021; NTDT half enrolled.","Developing HFpEF Phase 2 protocol; FDA interaction planned Q4 2021; Laura Williams appointed to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429217,"accession_number":"0001193125-21-214740","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2021-07-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Imara prices $50M public offering of 8.33M shares at $6.00 each; net proceeds ~$46.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 8,333,333 shares priced at $6.00/share for gross proceeds of $50M.","Net proceeds expected to be ~$46.8M after underwriting discounts and offering expenses.","Underwriters granted 30-day option to purchase up to 1,249,999 additional shares ($7.5M).","Closing expected July 16, 2021; Morgan Stanley, SVB Leerink, and Cantor are joint book-runners.","Company is a clinical-stage biotech focused on rare hemoglobin disorders; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429216,"accession_number":"0001193125-21-214102","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2021-07-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IMARA files July 2021 corporate presentation on hemoglobin disorder pipeline","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed a corporate slide presentation as Exhibit 99.1 under Item 8.01.","Presentation titled 'Advancing Novel Treatments for Hemoglobin Disorders' dated July 2021.","No financial results, guidance, or material operational updates provided.","Routine disclosure of materials used in investor meetings; no new events announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}